참고문헌
- Anfossi S, Giordano A, Gao H, et al (2014). High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS One, 9, 83113. https://doi.org/10.1371/journal.pone.0083113
- Chen C, Ridzon DA, Broomer AJ, et al (2005). Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res, 33, e179. https://doi.org/10.1093/nar/gni178
- Chen X, Ba Y, Ma L, et al (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006. https://doi.org/10.1038/cr.2008.282
- Cittelly DM, Das PM, Salvo VA, et al (2010). Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis, 31, 2049-57. https://doi.org/10.1093/carcin/bgq192
- Cortez MA, Bueso-Ramos C, Ferdin J, et al (2011). MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol, 8, 467-77. https://doi.org/10.1038/nrclinonc.2011.76
- Croce CM (2009). Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet, 10, 704-14. https://doi.org/10.1038/nrg2634
- Dawood S, Cristofanilli M (2011). Inflammatory breast cancer: what progress have we made? Oncol, 25, 264-73.
- Dawood S, Merajver SD, Viens P, et al (2011). International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol, 22, 515-23. https://doi.org/10.1093/annonc/mdq345
- Fang Z, Tang J, Bai Y, et al (2015). Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. J Exp Clin Cancer Res, 34, 86. https://doi.org/10.1186/s13046-015-0198-6
- Gaziel-Sovran A, Segura MF, Di Micco R, et al (2011). miR- 30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer Cell, 20, 104-18. https://doi.org/10.1016/j.ccr.2011.05.027
- Hagrass HA, Sharaf S, Pasha HF, et al (2015). Circulating microRNAs - a new horizon in molecular diagnosis of breast cancer. Genes Cancer, 6, 281-7.
- Hamdi K, Goerlitz D, Stambouli N, et al (2014). miRNAs in Sera of Tunisian patients discriminate between inflammatory breast cancer and non-inflammatory breast cancer. Springerplus, 3, 636. https://doi.org/10.1186/2193-1801-3-636
- Hatse S, Brouwers B, Dalmasso B, et al (2014). Circulating MicroRNAs as easy-to-measure aging biomarkers in older breast cancer patients: correlation with chronological age but not with fitness/frailty status. PLoS One, 9, 110644. https://doi.org/10.1371/journal.pone.0110644
- Hausler SF, Keller A, Chandran PA, et al (2010). Whole bloodderived miRNA profiles as potential new tools for ovarian cancer screening. Br J Cancer, 103, 693-700. https://doi.org/10.1038/sj.bjc.6605833
- Heneghan HM, Miller N, Kelly R, et al (2010). Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist, 15, 673-82. https://doi.org/10.1634/theoncologist.2010-0103
- Huang Z, Huang D, Ni S, et al (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26. https://doi.org/10.1002/ijc.25007
- Kodahl AR, Lyng MB, Binder H, et al (2014). Novel circulating microRNA signature as a potential non-invasive multimarker test in ER-positive early-stage breast cancer: a case control study. Mol Oncol, 8, 874-83. https://doi.org/10.1016/j.molonc.2014.03.002
- Konishi H, Ichikawa D, Komatsu S, et al (2012). Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Br J Cancer, 106, 740-7. https://doi.org/10.1038/bjc.2011.588
- Li X, Abdel-Mageed AB, Mondal D, et al (2013). MicroRNA expression profiles in differentiated thyroid cancer, a review. Int J Clin Exp Med, 6, 74-80.
- Liu YX, Long XD, Xi ZF, et al (2014). MicroRNA-24 modulates aflatoxin B1-related hepatocellular carcinoma prognosis and tumorigenesis. Biomed Res Int, 2014, 482926.
- Livak KJ, Schmittgen TD (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-8. https://doi.org/10.1006/meth.2001.1262
- Lodes MJ, Caraballo M, Suciu D, et al (2009). Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One, 4, 6229. https://doi.org/10.1371/journal.pone.0006229
- Lugli G, Cohen AM, Bennett DA, et al (2015). Plasma exosomal miRNAs in persons with and without alzheimer disease: altered expression and prospects for biomarkers. PLoS One, 10, 139233.
- Luo Q, Li X, Li J, et al (2013). MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol, 43, 1212-8. https://doi.org/10.3892/ijo.2013.2034
- Mitchell PS, Parkin RK, Kroh EM, et al (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA, 105, 10513-8. https://doi.org/10.1073/pnas.0804549105
- Nassar FJ, El Sabban M, Zgheib NK, et al (2014). miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study. PLoS One, 9, 107566. https://doi.org/10.1371/journal.pone.0107566
- Palmero EI, de Campos SG, Campos M, et al (2011). Mechanisms and role of microRNA deregulation in cancer onset and progression. Genet Mol Biol, 34, 363-70. https://doi.org/10.1590/S1415-47572011000300001
- Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12, 90. https://doi.org/10.1186/bcr2766
- Sayed D, Abdellatif M (2011). MicroRNAs in development and disease. Physiol Rev, 91, 827-87. https://doi.org/10.1152/physrev.00006.2010
- Schwarzenbach H, Hoon DS, Pantel K (2011). Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer, 11, 426-37. https://doi.org/10.1038/nrc3066
- Schwarzenbach H, Nishida N, Calin GA, et al (2014). Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol, 11, 145-56. https://doi.org/10.1038/nrclinonc.2014.5
- Shapira I, Oswald M, Lovecchio J, et al (2014). Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer, 110, 976-83. https://doi.org/10.1038/bjc.2013.795
- Shinden Y, Akiyoshi S, Ueo H, et al (2015). Diminished expression of MiR-15a is an independent prognostic marker for breast cancer cases. Anticancer Res, 35, 123-7.
- Simpson RJ, Lim JW, Moritz RL, et al (2009). Exosomes: proteomic insights and diagnostic potential. Expert Rev Proteomics, 6, 267-83. https://doi.org/10.1586/epr.09.17
- Tomimaru Y, Eguchi H, Nagano H, et al (2012). Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol, 56, 167-75. https://doi.org/10.1016/j.jhep.2011.04.026
- Van der Auwera I, Limame R, van Dam P, et al (2010). Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype. Br J Cancer, 103, 532-41. https://doi.org/10.1038/sj.bjc.6605787
- Wang F, Zheng Z, Guo J, et al (2010). Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. Gynecol Oncol, 119, 586-93. https://doi.org/10.1016/j.ygyno.2010.07.021
- Wu C, Wang C, Guan X, et al (2014). Diagnostic and prognostic implications of a serum miRNA panel in oesophageal squamous cell carcinoma. PLoS One, 9, 92292. https://doi.org/10.1371/journal.pone.0092292
- Wu Q, Lu Z, Li H, et al (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol, 2011, 597145.
- Wu Q, Wang C, Lu Z, et al (2012). Analysis of serum genomewide microRNAs for breast cancer detection. Clin Chim Acta, 413, 1058-65. https://doi.org/10.1016/j.cca.2012.02.016
- Yamauchi H, Woodward WA, Valero V, et al (2012). Inflammatory breast cancer: what we know and what we need to learn. Oncologist, 17, 891-9. https://doi.org/10.1634/theoncologist.2012-0039
- Yan LX, Huang XF, Shao Q, et al (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. RNA, 14, 2348-60. https://doi.org/10.1261/rna.1034808
- Zeng X, Xiang J, Wu M, et al (2012). Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One, 7, 46367. https://doi.org/10.1371/journal.pone.0046367
- Zhang G, Liu Z, Cui G, et al (2014). MicroRNA-486-5p targeting PIM-1 suppresses cell proliferation in breast cancer cells. Tumour Biol, 35, 11137-45. https://doi.org/10.1007/s13277-014-2412-0
- Zhu W, Qin W, Atasoy U, et al (2009). Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes, 2, 89. https://doi.org/10.1186/1756-0500-2-89
피인용 문헌
- Biological features of inflammatory breast cancer in North Africa: burden and research priorities vol.7, pp.2, 2018, https://doi.org/10.2217/bmt-2018-0002
- Expression signatures and roles of microRNAs in inflammatory breast cancer vol.19, pp.1, 2019, https://doi.org/10.1186/s12935-018-0709-6